[Transport of FT-207 to the blood, pancreatic juice, bile, and pancreatic tissue following rectal administration].
For the purpose of examining the transfer of antitumor drug into the blood, pancreatic juice, bile and pancreatic tissue, Futraful suppository (FT-sup) 1500 mg were given to 10 patients with pancreatic or bile duct malignancies, measuring Futraful and 5-FU concentrations in the pancreatic juice, bile and pancreatic tissue with lapse of time. Futraful and 5-FU concentrations of the pancreatic juice and bile reached to the maximum 4 hours after administration. The peaks of Futraful and 5-FU concentrations in the pancreatic juice and bile about 2 hours after the maximum values in the blood. 5-FU concentration in the pancreatic tissue was higher than that in the blood in every case. Transfer rate of Futraful to the pancreatic tissue was higher especially in the cases with higher pancreatic parenchymal ratio.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000378:metabolism; D001646:Bile / Q000378:metabolism*; D001692:Biological Transport; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000378:metabolism; D006801:Humans; D010179:Pancreas / Q000378:metabolism*; D010189:Pancreatic Juice / Q000378:metabolism*; D013488:Suppositories; D005641:Tegafur / Q000008:administration & dosage* / Q000378:metabolism; D014018:Tissue Distribution
D000970:Antineoplastic Agents; D013488:Suppositories; D005641:Tegafur; D005472:Fluorouracil